ABVC
Income statement / Annual
Last year (2024), ABVC BioPharma, Inc.'s total revenue was $509.59 K,
an increase of 234.31% from the previous year.
In 2024, ABVC BioPharma, Inc.'s net income was -$4.90 M.
See ABVC BioPharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
09/30/2016 |
09/30/2015 |
| Operating Revenue |
$509.59 K |
$152.43 K |
$969.78 K |
$355.80 K |
$483.05 K |
$701.72 K |
$6.96 K |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$763.00
|
$302.04 K
|
$286.42 K
|
$5.09 K
|
$18.72 K
|
$20.14 K
|
$228.89 K
|
$0.00
|
$32.00
|
$0.00
|
| Gross Profit |
$508.83 K
|
-$149.61 K
|
$683.37 K
|
$350.71 K
|
$464.33 K
|
$681.58 K
|
-$221.93 K
|
$0.00
|
-$32.00
|
$0.00
|
| Gross Profit Ratio |
1
|
-0.98
|
0.7
|
0.99
|
0.96
|
0.97
|
-31.91
|
0.3
|
-1
|
0.84
|
| Research and Development Expenses |
$179.27 K
|
$1.06 M
|
$2.69 M
|
$1.00 M
|
$549.66 K
|
$1.05 M
|
$988.72 K
|
$3.17 M
|
$10.00 M
|
$0.00
|
| General & Administrative Expenses |
$5.03 M
|
$5.55 M
|
$13.10 M
|
$11.05 M
|
$8.42 M
|
$3.09 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.03 M
|
$5.55 M
|
$13.10 M
|
$11.05 M
|
$8.42 M
|
$3.09 M
|
$1.57 M
|
$967.09 K
|
$997.20 K
|
$315.60 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$5.21 M
|
$6.62 M
|
$15.80 M
|
$12.06 M
|
$8.97 M
|
$4.14 M
|
$2.56 M
|
$4.14 M
|
$11.00 M
|
$315.60 K
|
| Cost And Expenses |
$5.21 M
|
$6.92 M
|
$16.08 M
|
$12.06 M
|
$8.99 M
|
$4.16 M
|
$2.79 M
|
$4.14 M
|
$11.00 M
|
$315.60 K
|
| Interest Income |
$87.36 K
|
$185.48 K
|
$187.82 K
|
$43.20 K
|
$71.05 K
|
$23.34 K
|
$5.21 K
|
$180.00
|
$361.00
|
$0.00
|
| Interest Expense |
$825.90 K
|
$1.31 M
|
$293.97 K
|
$227.21 K
|
$405.03 K
|
$482.01 K
|
$462.75 K
|
$103.46 K
|
$10.17 K
|
$0.00
|
| Depreciation & Amortization |
$200.92 K
|
$380.39 K
|
$23.80 K
|
$11.99 K
|
$37.14 K
|
$55.09 K
|
$43.61 K
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
-$4.34 M |
-$6.33 M |
-$15.20 M |
-$10.97 M |
-$10.37 M |
-$3.47 M |
-$5.92 M |
-$4.14 M |
-$11.00 M |
-$315.60 K |
| EBITDA Ratio |
-8.52
|
-41.53
|
-15.67
|
-30.84
|
-21.47
|
-4.95
|
-851.53
|
-1250.31
|
17.53
|
-9.61
|
| Operating Income Ratio |
-9.23
|
-44.39
|
-15.59
|
-32.9
|
-17.61
|
-4.93
|
-400.31
|
-1295.06
|
-343665.47
|
-9.61
|
| Total Other Income/Expenses Net |
-$664.33 K
|
-$1.26 M
|
-$400.18 K
|
$495.14 K
|
-$2.31 M
|
-$551.50 K
|
-$3.65 M
|
-$103.28 K
|
-$9.67 K
|
$0.00
|
| Income Before Tax |
-$5.37 M
|
-$8.02 M
|
-$15.51 M
|
-$11.21 M
|
-$10.81 M
|
-$4.01 M
|
-$6.43 M
|
-$4.24 M
|
-$11.01 M
|
-$315.60 K
|
| Income Before Tax Ratio |
-10.54
|
-52.65
|
-16
|
-31.51
|
-22.39
|
-5.71
|
-924.33
|
-2199.62
|
-140842.59
|
-9.61
|
| Income Tax Expense |
-$110.54 K
|
$256.01 K
|
$797.78 K
|
$825.02 K
|
-$220.35 K
|
-$77.04 K
|
-$365.10 K
|
$830.00
|
$836.00
|
$0.00
|
| Net Income |
-$4.90 M
|
-$7.79 M
|
-$16.42 M
|
-$12.84 M
|
-$9.79 M
|
-$3.64 M
|
-$5.58 M
|
-$4.24 M
|
-$11.01 M
|
-$315.60 K
|
| Net Income Ratio |
-9.62
|
-51.09
|
-16.93
|
-36.08
|
-20.27
|
-5.19
|
-801.52
|
-1579.47
|
-140868.72
|
-9.61
|
| EPS |
-0.42 |
-1.8 |
-5.2 |
-5.1 |
-5 |
-2.1 |
-4.69 |
-3.58 |
-10.21 |
-0.0115 |
| EPS Diluted |
-0.42 |
-1.8 |
-5.2 |
-5.1 |
-5 |
-2.1 |
-4.69 |
-3.58 |
-10.8 |
-0.0115 |
| Weighted Average Shares Out |
$11.67 M
|
$4.34 M
|
$3.17 M
|
$2.51 M
|
$1.97 M
|
$1.75 M
|
$1.19 M
|
$1.18 M
|
$1.17 M
|
$2.81 M
|
| Weighted Average Shares Out Diluted |
$11.67 M
|
$4.34 M
|
$3.17 M
|
$2.51 M
|
$1.97 M
|
$1.75 M
|
$1.19 M
|
$1.19 M
|
$1.17 M
|
$2.81 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
